After approval REDECTANE® could be used before every planned surgical removal of a renal tumour in order to determine whether it is a clear cell renal cell carcinoma. In the Company’s view, using REDECTANE® and PET/CT for diagnosis could greatly enhance the precision of renal cancer diagnosis and thus bring about crucial changes in therapy monitoring. The therapy planning for renal cancer patients could improve fundamentally and unneccessary surgery could be avoided. Furthermore, REDECTANE® may also prove suitable for diagnosing other kinds of tumours. Wilex is not aware of a similar imaging procedure existing today.